Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 11/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 10/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.47 |
| ▸ | PSMB10 | P40306 | 7/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664900 | 1.00 | BCL2 (0.50) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4663324 | 1.00 | BCL2 (0.50) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4664783 | 0.92 | CTSS (0.48) | — | |
| SCHEMBL4664891 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4666840 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4664987 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4664989 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4664897 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4664894 | 0.84 | BCL2 (0.51) | BCL2PTPN1PSMB1PSMB9PSMB5 | |
| SCHEMBL4662978 | 0.81 | CTSK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | BCL2 442/4885PTPN1 2489/4885PSMB1 197/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | BCL2 442/4885PTPN1 2489/4885PSMB1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.